Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy

<div>LVEF (a) and GLS (b) in breast cancer patients with metabolic syndrome and noncancer patients with metabolic syndrome.</div>

Cardiology Research and Practice

fig1

Figure 1

Figure 1: Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy 

Figure 1 | Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy 